GB2450753A — Composition comprising inverse agonist and neutral antagonist of the CB1 and / or CB2 receptor
Assigned to GW Pharma Ltd · Expires 2009-01-07 · 17y expired
What this patent protects
A pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CBl and / or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CBl and / or CB2 receptor. Preferably both the inverse ago…
USPTO Abstract
A pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CBl and / or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CBl and / or CB2 receptor. Preferably both the inverse agonist of the CBl and / or CB2 receptor and the neutral antagonist of the CBl and / or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.